Skip to content

BAsel Stent KostenEffektivitaets Trial (Basel Stent cost-effectiveness trial)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN75663024
Enrollment
826
Registered
2006-11-03
Start date
2003-05-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary artery disease Circulatory System Coronary artery disease

Interventions

PCI in a real world setting (chronic and acute disease). Patients randomised 2:1 to drug eluting versus bare metal stents.

Sponsors

University Hospital Basel (Switzerland)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Coronary artery disease suitable for interventional therapy. All patients referred for cardiac catheterisation and subsequent Percutaneous Coronary Intervention (PCI) irrespective of clinical indication, who are able to provide written informed consent.

Exclusion criteria

Exclusion criteria: 1. In-stent-restenosis 2. Target vessel diameter equal to or greater than 4 mm 3. No informed consent

Design outcomes

Primary

MeasureTime frame
Six month cost-effectiveness with effectiveness defined as reduction of major adverse cardiac events - i.e., cardiac death, non-fatal myocardial infarction and target vessel revascularisation.

Secondary

MeasureTime frame
1. Mortality from other cause, target vessel ischemia by myocardial perfusion Single Photon Emission Computed Tomography (SPECT). 2. Effectiveness of DES in patients with myocardial infarction and saphenous vein graft disease. 3. Cost-effectiveness as defined above after 18 and 36 months.

Countries

Switzerland

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 27, 2026